Results 211 to 220 of about 93,014 (296)

Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy. [PDF]

Life (Basel)
Yakobson A, Abu Salamah F, Alatawneh I, Cohen AY, Valdman-Grinshpoun Y, Malek Y, Gothelf I, Abu Jama A, Abu Yasin N, Abu Juda M, Soklakova A, Meirovitz A, Shalata W.   +12 more
europepmc   +1 more source

Development of Betalactam‐Predictor: A Clinical Decision Tool for Delabeling Low‐Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy

Allergy, EarlyView.
BL‐Predictor has emerged as a new tool for delabeling penicillin allergy. External validation has shown a specificity of 93% for detecting low‐risk patients. This score could potentially reduce diagnostic costs and the negative consequences associated with incorrect antibiotic allergy labels.
Marina Labella, Rafael Nuñez, Inmaculada Doña, Julia Rodríguez de Guzmán, Esther Moreno, Lene Heise Garvey, Jose Julio Laguna, Annick Barbaud, Patrizia Bonnadona, Jonas Bredtoft Boel, Holger Mosbech, Giovanna Sfriso, Mariana Castells, Elizabeth Phillips, María José Torres   +14 more
wiley   +1 more source

Elucidating the Multi-Target Anti-Pruritic Mechanism of <i>Polygonatum odoratum</i> via Integrated Network Pharmacology, Molecular Simulations, and GEO Dataset Validation. [PDF]

Curr Issues Mol Biol
Chen J, Liu C, Chen X, Yu G, Li Z, Yang H.   +5 more
europepmc   +1 more source

Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience

Addiction, EarlyView.
Julien Cabé, Georges Brousse
wiley   +1 more source

Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series. [PDF]

Cureus
Chakravadhanula U, Nagarajan M, Bhat S.
europepmc   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

Allergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery, Rüçhan Ekren, Emilie Bérard, Aurélie Du‐Thanh, Hugo Rimet, Fatma Jendoubi, Vanina Lenief, Nadia Raison‐Peyron, Amel Bouznad, Maria P. Konstantinou, Jonathan Rioual, Lilian Basso, Juliette Mouiren, Manon Boussier, Brigitte Milpied, Cristina Bulai Livideanu, Louise Jaulent, Florence Hacard, Marine A. Lefevre, Audrey Nosbaum, Julien Seneschal, Marc Vocanson, Carle Paul, Nicolas Gaudenzio, Marie Tauber, on behalf of the French Atopic Dermatitis Network from de GREAT Research group   +25 more
wiley   +1 more source

Polymorphic eruption of pregnancy successfully treated with dupilumab in the postpartum period: A case report. [PDF]

SAGE Open Med Case Rep
Moschella A, Glockler-Lauf SD, Hosseini N, Colantonio S.   +3 more
europepmc   +1 more source

Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

Allergy, EarlyView.
This study evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Patients who switched from LTP to donidalorsen experienced a 67.6% reduction in HAE attack rates over 52 weeks.
Marc A. Riedl, Jonathan A. Bernstein, Joshua S. Jacobs, Timothy Craig, William R. Lumry, H. James Wedner, Aleena Banerji, Selina Gierer, Andrew Smith, Michael E. Manning, Francesca Perego, Laura Bordone, Sabrina Treadwell, Tao Lin, Kenneth B. Newman, Aaron Yarlas, Danny M. Cohn   +16 more
wiley   +1 more source

Atopic Dermatitis in Children: Differential Diagnosis and Mimickers. [PDF]

Children (Basel)
Türe Avcı B, Çetinarslan T, Türel Ermertcan A, Fölster-Holst R.   +3 more
europepmc   +1 more source

Hypersensitivity to Excipients in Drugs: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved.
Lene H. Garvey, Knut Brockow, Annick Barbaud, Charlotte G. Mortz, Gianfranco Calogiuri, Asli Gelincik, Osman O. Yeğit, Alla Nakonechna, Annette Wagner, Rik Schrijvers, Toon Ieven   +10 more
wiley   +1 more source